Board of Directors
Director, Center for Implementation Sciences,
Global Health Sciences
University of California, San Francisco
Board Chair since June 2016
Board member since 2008
Eric Goosby has worked in HIV/AIDS research, treatment, advocacy and policy for more than 25 years and is a leading global expert and champion in fighting the disease.
From 2009 to 2013, as US Global AIDS Coordinator, Goosby directed the US strategy for addressing HIV/AIDS globally and led the implementation of the President's Emergency Plan for AIDS Relief (PEPFAR) under President Obama. He also served as Founding Director of the Office of Global Health Diplomacy at the US Department of State under Secretary of State Hillary Clinton. In 2015, United Nations (UN) Secretary-General Ban Ki-moon appointed him as Special Envoy on Tuberculosis.
He began his career treating HIV/AIDS patients at San Francisco General Hospital, where he was Associate Medical Director from 1984-1991. Goosby joined the US Department of Health and Human Services in 1991 as the first Director of the Ryan White Care Act and served as Deputy Director of the White House National AIDS Policy Office and Director of the Office of HIV/AIDS Policy from 1995-2000. He also was the founding CEO and Chief Medical Officer of Pangaea Global AIDS Foundation.
Goosby holds an MD from University of California, San Francisco, where he completed his residency and a two-year Kaiser Fellowship specializing in infectious diseases.
President, AMV Advisors
Vice Chair since June 2016
Chair of the Audit & Finance Committee
Board member since 2008
Anne VanLent is the Founder and President of AMV Advisors, a strategic and financial management consultancy that serves emerging-growth and early stage companies in the life sciences arena. With more than 30 years of leadership experience at research and development, biotechnology and pharmaceutical firms, VanLent guides emerging life sciences firms in financial operations, strategic funding and transaction support and mentoring high-potential executives.
An experienced, seasoned director and audit chair of publicly traded companies, VanLent currently serves on the Board of Directors of four biopharmaceutical companies, including Applied Genetic Technologies Corporation, Aviragen Pharmaceuticals, Inc., Novelion Therapeutics, Inc. and Ocera Therapeutics, Inc. She also served on the Boards of Onconova Therapeutics, Integra Life Sciences Holding Corporation and Penwest Pharmaceuticals, among others.
Previously, she was Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., Executive Vice President of Portfolio Management and Vice President of Ventures and Licensing at Sarnoff Corporation, and Executive Vice President and Chief Financial Officer at The Liposome Company, Inc. She holds a bachelor’s degree in physics from Mount Holyoke College.
Chief Operating Officer, Barnard College
Board member since November 2016
Roberg Goldberg has been Chief Operating of Barnard College since 2014. Previously, he served as the Director of the Office of US Foreign Assistance Resources at the US Department of State, where he was been responsible for managing all aspects of the $32 billion foreign assistance budget for the State Department and the US Agency for International Development (USAID), including planning, budget formulation and execution, and program performance. He also oversaw the Department’s budget formulation information technology system and the foreignassistance.gov website.
Prior to his position at the State Department, he served for five years as the Deputy Associate Director for International Affairs at the Office of Management and Budget, the senior career official responsible for budget and policy matters related to the US government’s international affairs program. In addition to the State Department and USAID, he worked with and oversaw programs managed by other international agencies including the Peace Corps.
Goldberg holds both a bachelor’s degree in international relations and a master’s degree in international affairs from The George Washington University.
Professor, Woodrow Wilson School & Department of Molecular Biology
Board member since 2012
Adel Mahmoud is an expert on infectious diseases, global health and vaccine research and development. He is a fellow of the American College of Physicians and a member of the National Academy of Medicine and of the National Academy of Sciences.
Previously, he was President of Merck Vaccines, where he led the effort to develop four new vaccines: Gardasil® to prevent cervical cancer and other human papillomavirus diseases; RotaTeq®, to prevent infantile rotavirus gastroenteritis; Zostavax®, to prevent shingles; and ProQuad®, to prevent measles, mumps, rubella and varicella. He also served on the US National Advisory Allergy and Infectious Diseases Council and as President of the Central Society for Clinical Research and the International Society for Infectious Diseases.
Mahmoud is former Chairman of Medicine and Physician-in-Chief at Case Western University School of Medicine and University Hospitals of Cleveland. He holds both the Bailey K. Ashford Award from the American Society of Tropical Medicine and Hygiene and the Squibb Award from the Infectious Diseases Society of America. He earned an MD from the University of Cairo and a PhD from the University of London, School of Hygiene and Tropical Medicine.
Past President and Chief Executive Officer
Board member since 2012
Purnima Mane is an internationally respected expert on sexual and reproductive health. Most recently, she served as the President and CEO of Pathfinder International, a non-profit that champions sexual and reproductive health and rights worldwide.
Mane has held several distinguished posts with the United Nations, including Assistant Secretary-General, Deputy Executive Director of the United Nations Population Fund, and Director of Policy, Evidence and Partnership at the Joint United Nations Programme on HIV/AIDS (UNAIDS), where she led the development of the 2004 HIV Prevention Policy and the first UNAIDS Strategic Plan (1996-2000). She also served as Chief Fund Portfolio Director and Director, Asia, of the Global Fund to Fight AIDS, Tuberculosis and Malaria; as Vice President and Director of International Programs at the Population Council; and held senior management positions while at the World Health Organization’s Global Programme on AIDS.
She holds a PhD from Tata Institute of Social Sciences in Mumbai, India, where she was an Associate Professor. Before joining UNAIDS, she worked on public health and gender-related issues in India for more than 13 years.
Founder, Chair and Executive Director
Congolese Foundation for Medical Research
Board member since 2015
Francine Ntoumi is Founder, Chair and Executive Director of the Congolese Foundation for Medical Research and an expert in the molecular epidemiology and immunology of malaria.
She is highly involved in developing African health research capacities through the Central Africa Network on Tuberculosis, HIV/AIDS and Malaria, the first network of excellence in sub-Saharan Africa supported by the European and Developing Countries Clinical Trials Partnership (EDCTP) for building capacities for the conduct of clinical trials. She also is Senior Lecturer in Immunology at Marien NGouabi University in the Republic of Congo, an Associate Professor at the University of Tübingen in Germany and serves on the Global Health Scientific Advisory Board of the Bill & Melinda Gates Foundation. Formerly Senior Scientific Officer at EDCTP, in 2005 she became the first African leader of the Multilateral Initiative on Malaria, an organization she served for 10 years through 2010.
Ntoumi’s accolades include the 2016 Christophe Mérieux Prize, the 2015 Georg Forster Prize and the 2012 African Union Kwame Nkrumah Regional Scientific Award for women. She is a laureate of the Réseau International des Congolais de l’Extérieur for her contributions in health research and holds a PhD from Université Pierre et Marie Curie in Paris, France.
Chairman of GSK Vaccines
Board member since 2015
Moncef Slaoui specializes in the research and development of vaccines and was recognized as one of Fortune’s “50 Greatest World Leaders” in 2016 for his work in under-researched diseases common in the developing world.
As a member of GSK’s Board of Directors, he continues to oversee its venture capital arm, SR One, and other venture capital partnerships, as well as its Bioelectronics R&D strategy. He also sits on the Board of Directors of the Pharmaceutical Research and Manufacturers of America Foundation and the Biotechnology Industry Organization and on the Advisory Board of the Qatar Foundation and the National Institutes of Health Advisory Committee to the Director.
Previously, he was Chairman of Research and Development (R&D) at GSK, where he led an overhaul of the company’s pharmaceutical R&D and was responsible for commercial pursuits such as new product launches and lifecycle management. While leading vaccine R&D at GSK Vaccines, he engineered the development of the vaccines Rotarix®, to prevent infantile rotavirus gastroenteritis; Synflorix®, to prevent pneumococcal disease; and Cervarix®, to prevent cervical cancer.
Slaoui earned a PhD in molecular biology and immunology from the Université Libre de Bruxelles in Belgium, completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston, and was a Professor of Immunology at the University of Mons, Belgium.
Interim Executive Director, The Global Fund to Fight AIDS, TB and Malaria
Board member since 2011
Marijke Wijnroks is Interim Executive Director of the Global Fund to fight AIDS, Tuberculosis and Malaria (Global Fund), where she focuses on gender and human rights and on engaging with partners in the cause of global health. The Global Fund raises and invests nearly US$4 billion a year to support programs run by local experts in countries and communities most in need.
She has more than 25 years of experience in global health and development work, serving in the government, at the United Nations and in civil society, and working in Africa, Asia, Latin America and Europe. Previously, she was Ambassador for HIV/AIDS and Sexual and Reproductive Health and Rights, and Deputy Director of the Social Development Department in the Ministry of Foreign Affairs in the Netherlands. There she oversaw policy and strategy development in areas related to HIV/AIDS, sexual and reproductive health and rights, and civil society; advised senior leadership on development and health issues; and represented the Dutch government on the boards of several leading organizations, including the Global Fund, Gavi and UNAIDS.
She earned a medical degree from Maastricht University in the Netherlands and a degree in tropical health and medicine from the Institute for Tropical Medicine in Belgium.